2-chloro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide | 1567836-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-chloro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide
• 英文别名: 2-Chloro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide；2-chloro-N-[5-[5-(2-methyl-1-oxo-3H-isoindol-5-yl)thiophen-2-yl]pyridin-3-yl]-4-(trifluoromethyl)benzenesulfonamide
• CAS: 1567836-68-3
• 化学式: C₂₅H₁₇ClF₃N₃O₃S₂
• 分子量: 564.008
• InChiKey: XLEBZBGOJIXCLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氯-4-(三氟甲基)苯磺酰氯 、 5-(5-(5-aminopyridin-3-yl)thiophen-2-yl)-2-methylisoindolin-1-one 以to give the title compound (26) as a beige solid (61%)的产率得到2-chloro-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide
  参考文献：
  名称：

  PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF

  摘要：

  公式（1a）的化合物及其药学上可接受的盐、溶剂化物和水合物，以及相关的调节细胞穿孔素活性的方法：其中环A选自6-10成员芳基、5-6成员环烷基、5-6成员杂芳基或5-6成员杂环烷基，其中杂芳基和杂环烷基环中至少包含一个选自N、O或S的杂原子；环A、环烷基、杂芳基或杂环烷基环可以选择地被1到3个取代基所取代，所述取代基选自卤素、硝基、-C1-Ce烷基、-C1-Ce氨基烷基、-C1-C6羟基烷基、-卤基C1-C6烷基、-C1-C6烷氧基、-卤基C1-C

  公开号：

  US20150218150A1

文献信息

• Substituted arylsulphonamides as inhibitors of perforin-mediated lysis
  作者：Julie A. Spicer、Christian K. Miller、Patrick D. O'Connor、Jiney Jose、Kristiina M. Huttunen、Jagdish K. Jaiswal、William A. Denny、Hedieh Akhlaghi、Kylie A. Browne、Joseph A. Trapani

  DOI：10.1016/j.ejmech.2017.05.048

  日期：2017.9

  The structure-activity relationships for a series of arylsulphonamide-based inhibitors of the pore forming protein perforin have been explored. Perforin is a key component of the human immune response, however inappropriate activity has also been implicated in certain auto-immune and therapy induced conditions such as allograft rejection and graft versus host disease. Since perforin is expressed exclusively by cells of the immune system, inhibition of this protein would be a highly selective strategy for the immunosuppressive treatment of these disorders. Compounds from this series were demonstrated to be potent inhibitors of the lytic action of both isolated recombinant perforin and perforin secreted by natural killer cells in vitro. Several potent and soluble examples were assessed for in vivo pharmacokinetic properties and found to be suitable for progression to an in vivo model of transplant rejection. (C) 2017 The Authors. Published by Elsevier Masson SAS.
• US9896443B2
  申请人：——

  公开号：US9896443B2

  公开（公告）日：2018-02-20